A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
List view / Grid view
Filter the results
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.
A new study has shown that while chloroquine protects African green monkey kidney cells from SARS-CoV-2 infection, it does not protect human lung cells.
Researchers have suggested that neutrophils, which contribute to the development of ARDS in COVID-19 patients, could be diverted from the lungs by rod-shaped particles in a new form of treatment.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
The identification and validation of novel drug targets is a challenging process for drug discovery programmes.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.